非小细胞肺癌一线治疗方案erlotinib与cg化疗的成本—效果分析.pdf

VersusCG Cost—EffectivenessofErlotinib Analysis InNSCLCFirst-line Chemotherapy Therapy Abstract： objective Our cost—effectivenessbetweenerlotinib study compared and in monotherapy therapy withadvanced to a EGFR NSCLC patients mutation—positiveprovide valuablereferenceforrational、safeandeconomicuseofanticancer drug． Methods This wasbasedonthedataandinformationfroma III study phase clinical OPTIMALa 3A trials(the trial)andlargegradehospital．From the oftheChinesehealthcare perspective cost—effectivenessbetweenerlotinib and monotherapycarboplatinplus in withadvancedEGFR gemcitabine(CG)combinationtherapypatients NSCLC．Incrementalcosteffectiveness mutation—positive ratios(ICER) wasusedasevaluationindicator．Markovmodelwasusedto data analyse and Pro2009wasusedtoestablishthemodeland TreeAge export outcomeswithall data．Toallowforuncertaintieswithin necessary the andtoestimatethe model parameters robustness，one—waysensitivity and were analysisp